Overview
VERU market data
Price History
VERU price chart · 1M
- O
- 2.80
- H
- 2.80
- L
- 2.72
- C
- 2.75
- Vol
- 8,736.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $2.80
- Previous Close
- $2.81
- Day High
- $2.80
- Day Low
- $2.72
- 52 Week High
- $7.23
- 52 Week Low
- $2.06
- 7 Day Return
- +6.38%
- 30 Day Return
- +23.87%
- 90 Day Return
- +16.77%
- 1 Year Return
- +22.22%
- Daily Notional Volume
- $24K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.80 Diluted earnings per share over the trailing twelve months.
- Beta
- -1.19 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -223.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.05 – $7.33 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $44.4M · P/B 3.04 · P/S 2.63.
Company News
Veru shares are trading higher after the company reported better-than-expected Q3 EPS results.Benzinga · Aug 10, 2026, 3:06 PM
8-K filing — VERU INC. (VERU)SEC EDGAR · Aug 10, 2026, 11:00 AM
Veru Q3 EPS $(0.30) Beats $(0.32) EstimateBenzinga · Aug 10, 2026, 10:35 AM
Veru Says USPTO Issued Notice Of Allowance For Patent Covering Enobosarm Combined With Weight Loss Drugs, With Protection Until At Least October 2044Benzinga · Aug 4, 2026, 12:36 PM
Veru Completes Patient Enrollment In Phase 2b PLATEAU Clinical Trial To Evaluate Effect Of Oral Enobosarm 3 Mg Versus To Treat ObesityBenzinga · Jul 27, 2026, 12:14 PM
Veru Announces $21.8M Sales ATM Program With Oppenheimer, CanaccordBenzinga · Jul 2, 2026, 8:20 PM
Canaccord Genuity Maintains Buy on Veru, Maintains $25 Price TargetBenzinga · Jun 4, 2026, 4:40 PM
Veru Shares Resume TradeBenzinga · Jun 4, 2026, 4:30 PM
Veru Shares Halted On Circuit Breaker To The Upside, Stock Now Up 167.56%Benzinga · Jun 4, 2026, 4:20 PM
Veru Strikes Clinical Supply Agreement With Novo Nordisk To Mull Combination Of Enobosarm With WegovyBenzinga · Jun 4, 2026, 12:40 PM